Cancer Chemotherapy and Pharmacology

, Volume 35, Issue 6, pp 506–510 | Cite as

Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer

  • M. O. Nicoletto
  • R. Padrini
  • H. Koussis
  • A. Rosabian
  • S. Aversa
  • L. Endrizzi
  • P. Azzoni
  • M. Palumbo
  • M. V. Fiorentino
Original Article Mitoxantrone Infusion, Advanced Epithelial Ovarian Cancer, Mitoxantrone Stability


Mitoxantrone has shown moderate activity in advanced epithelial ovarian cancer following intermittent i.v. administration. Experiments and clinical data suggest that long-term continuous drug infusion may achieve a better therapeutic result with less toxicity. This hypothesis was tested in patients with advanced ovarian cancer who had been pretreated with other agents. Mitoxantrone was infused continuously in 21-day courses beginning every 6 weeks. If severe toxicity did not occur, the infusion rate was increased by 0.1–0.2 mg/m2 per day. The mitoxantrone solution proved to be stable over the 21-day infusion period. For ethical reasons an optimal two-stage design was employed. The trial was interrupted at the end of the first recruitment stage because the target of 3 responses out of 13 patients had not been achieved (only 1 patient had a partial response). Hematologic toxicity was observed in 11 patients, and 2 of them had a catheter occlusion. In conclusion, we found that 21-day of infusion of mitoxantrone apparently has no clinical benefit as compared with bolus administration in patients with advanced ovarian cancer.

Key words

Mitoxantrone infusion Advanced epithelial ovarian cancer Mitoxantrone stability 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alberts DS, Surwit EA, Peng YM, Closkey TM, Riviest R, Graham V, McDonald L, Roe D (1988) Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 48:5874Google Scholar
  2. 2.
    Bast RC Jr, Klug TL, St. John ES, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883Google Scholar
  3. 3.
    Bertelsen K, Hansen MK, Pedersen PH, Larsen G, Nyland M, Jacobsen M, Andersen JE (1988) The prognostic therapeutic value of second-look laparotomy in advanced ovarian cancer. Br J Obstet Gynecol 95:1231Google Scholar
  4. 4.
    Blochl-Daum B, Rainer EH, Jakesz R, Salzer H, Steger G, Schuller J, Gunther E, Proksch B, Ehninger G (1988) Escalating dose regimen of intraperitoneal mitoxantrone: phase I study—clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol 24:1133Google Scholar
  5. 5.
    Copeland LJ, Gershenson DM (1986) Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy. Obstet Gynecol 68:837Google Scholar
  6. 6.
    Drewinko B, Yang LY, Barlogie B, Trujillo JM (1983) Comparative cytotoxicity bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro. Cancer Res 43:2648Google Scholar
  7. 7.
    FIGO Cancer Committee (1986) Staging announcement. Gynecol Oncol 25:383Google Scholar
  8. 8.
    Fiorentino MV, Nicoletto MO, Stefani GP, Salvagno L, Tredese F (1988) A phase II trial with mitoxantrone in pretreated epithelial ovarian cancer. Proceedings 6th Mediterranean Congress of Chemotherapy, Taormina, 22–27 May, p 504Google Scholar
  9. 9.
    Greidanus J, Vries EGE de, Mulder NH, Sleijfer DT, Uges DRA, Oosterhuis B, Willemse PHBM (1989) A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 7:790Google Scholar
  10. 10.
    Kaminer LS, Choi KE, Daley KM, Larson RA (1990) Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer 65:2619Google Scholar
  11. 11.
    Lawton F, Blakledge G, Mould J, Latief T, Watson R, Chetiyawardana AD (1987) Phase II study of mitoxantrone in epithelial ovarian cancer. Cancer Treat Rep 71:627Google Scholar
  12. 12.
    Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis L Jr (1990) Phase II study of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 1:146Google Scholar
  13. 13.
    McVie JG, Rodenhuis S, Dubbelman R, Varossieau FJ, Bokkel Huinink WW ten (1987) Clinical pharmacokinetics of intraperitoneal mitoxantrone in ovarian cancer. Proc Am Soc Clin Oncol 6A:156Google Scholar
  14. 14.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207Google Scholar
  15. 15.
    Nicoletto MO, Padrini R, Ferrazzi E, Nascimben O, Visonà E, Tumolo S, Palumbo M, Costa L, Vinante O, Monfardini S, Fiorentino MV (1993) Phase-II study of intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. Eur J Cancer 29A:1242Google Scholar
  16. 16.
    Peng YM, Ormberg D, Alberts DS (1982) Improved highperformance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. J Chromatogr 233:235Google Scholar
  17. 17.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1Google Scholar
  18. 18.
    Smith IE (1983) Mitoxantrone (Novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10:103Google Scholar
  19. 19.
    Van Belle SJP, Schoemaker TJ, Verwey SL, Paalman ACA, McVie JGJ (1985) ion-paired high performance liquid chromatographic determination of mitoxantrone in physiological fluids. J Chromatogr 337:73Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • M. O. Nicoletto
    • 1
  • R. Padrini
    • 2
  • H. Koussis
    • 1
  • A. Rosabian
    • 3
  • S. Aversa
    • 1
  • L. Endrizzi
    • 4
  • P. Azzoni
    • 5
  • M. Palumbo
    • 6
  • M. V. Fiorentino
    • 1
  1. 1.Medical Oncology DepartmentPadova General HospitalPadovaItaly
  2. 2.Department of PharmacologyUniversity of PadovaPadovaItaly
  3. 3.Medical Oncology DepartmentThiene-Schio General HospitalVicenzaItaly
  4. 4.Medical Oncology DepartmentBassano General HospitalVicenzaItaly
  5. 5.Medical DepartmentBussolengo HospitalVeronaItaly
  6. 6.Department of Pharmaceutical SciencesUniversity of PadovaPadovaItaly

Personalised recommendations